AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|
22.8 C
New York
Thursday, September 10, 2026

Tag: presentation

newssourceFORcompanyinformationcontent1releasesmarket

Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results

FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025.

Perpetua Resources Announces Webinar to Provide Update on Successful Financing and Next Steps to Unlock Value at the Stibnite Gold Project

BOISE, Idaho, June 16, 2025 /PRNewswire/ - Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") is pleased to...

MEDIA INVITATION – ADM Aéroports de Montréal Technical briefing – Mitigation measures and Flight Plan 2028

MONTRÉAL, June 16, 2025 /CNW/ - With summer just around the corner and work on the major Flight Plan 2028 projects getting underway, ADM...

FibroBiologics to Present at the BIO International Convention 2025

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.

SUNation Energy Retains Nasdaq Listing

SUNATION ENERGY RETAINS NASDAQ LISTING

Subsea 7 S.A. – 2Q25 earnings call notification

Luxembourg – 16 June 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) will publish its second quarter 2025 results for the period ended 30 June 2025 on Thursday 31 July 2025 at 08:00 CET.

Join the Cross Border Fest in Kefamenanu, NTT 2025 — Free Entry!

Get ready for an unforgettable experience at the border of Indonesia and Timor Leste! KEFAMENANU, Indonesia, June 16, 2025 /PRNewswire/ -- The Ministry of Tourism,...

Tokyo Gas Wins CNCF End User Case Study Contest for Driving Cloud Native Agility with Kubernetes, Argo and Istio

Company to present digital platform modernization success at KubeCon + CloudNativeCon Japan 2025 TOKYO, June 15, 2025 /PRNewswire/ -- The Cloud Native Computing Foundation® (CNCF®), which...

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  presented the subgroup analysis data from the Phase III COMPASSION-16...

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPresentation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers